Results 151 to 160 of about 99,253,553 (299)

Changes in Muscle Strength Following Semaglutide Treatment in Adults: A Systematic Review With Meta‐Analysis of Handgrip Strength

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To systematically review and quantitatively synthesize within‐group changes in skeletal muscle strength following semaglutide treatment in adults. Materials and Methods This PRISMA 2020 systematic review was registered in PROSPERO (CRD420251185935).
Luís Guilherme Machado, Pedro Henrique Siedschlag Schmidt, Guido Tasca Petroski, Geraldo Lucas Lopes Costa, Letícia Vieira dos Santos Ribeiro, João Victor Ramos Da Cruz, Graziela De Luca Canto, Alexandre Hohl, Marcelo Fernando Ronsoni, Simone van de Sande‐Lee   +9 more
wiley   +1 more source

Immunohistochemical Localization of Alogliptin, a DPP-4 Inhibitor, in Tissues of Normal and Type 2 Diabetes Model Rat. [PDF]

Acta Histochem Cytochem, 2022
Yamamoto Y, Ura K, Matsukawa T, Saita T, Shin M.   +4 more
europepmc   +1 more source

Neuropsychiatric Outcomes Associated With GLP‐1 Receptor Agonist Use in Medicare Beneficiaries With Type 2 Diabetes: Variation by Treatment Pattern and Obesity Status

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Glucagon‐like peptide‐1 (GLP‐1) receptors are expressed in brain regions governing mood, reward and stress, yet the neuropsychiatric effects of GLP‐1 receptor agonist (GLP‐1 RA) therapy remain poorly characterized. We estimated associations between GLP‐1 RA use and neuropsychiatric disorders and variation by obesity status and treatment ...
Seo Hyon Baik, Fitsum Baye, Haotian Xian, Kin Wah Fung, Clement J. McDonald   +4 more
wiley   +1 more source

DPP-4 Inhibitor in Type 2 Diabetes Mellitus Patient with Non-Alcoholic Fatty Liver Disease: Achieving Two Goals at Once? [PDF]

Endocrinol Metab (Seoul), 2022
Bae JC.
europepmc   +1 more source

Metformin and Severe Post‐COVID‐19 Outcomes Among Individuals With Diabetes Mellitus

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims We evaluated the relationship between metformin, one of the most commonly prescribed medications for individuals with diabetes, and COVID‐19 sequelae. Materials and Methods We evaluated a retrospective cohort of individuals in the National Clinical Cohort Collaborative with Type 2 diabetes mellitus and COVID‐19 who were prescribed ...
Zachary B. Dozier, Lin‐Chiun Wang, Yunwen Ji, A. Jerrod Anzalone, Oluwasolape Olawore, Ryan Hafen, Eric Hurwitz, Manav Kumar, Rena C. Patel, Ariana Budhihartanto, Mark van der Laan, John M. Colford Jr., Alan E. Hubbard, John B. Buse, Steven G. Johnson, Jane Reusch, Lauren E. Chan, Richard Moffitt, Rachel Wong, Carolyn Bramante, on behalf of the National Clinical Cohort Collaborative (N3C) Consortium, Adam B. Wilcox, Adam M. Lee, Alexis Graves, Jerrod) Anzalone, Amin Manna, Amit Saha, Amy Olex, Andrea Zhou, Andrew E. Williams, Andrew Southerland, Andrew T. Girvin, Anita Walden, Anjali A. Sharathkumar, Benjamin Amor, Benjamin Bates, Brian Hendricks, Brijesh Patel, Caleb Alexander, Carolyn Bramante, Cavin Ward‐Caviness, Charisse Madlock‐Brown, Christine Suver, Christopher Chute, Christopher Dillon, Chunlei Wu, Clare Schmitt, Cliff Takemoto, Dan Housman, Davera Gabriel, David A. Eichmann, Diego Mazzotti, Don Brown, Eilis Boudreau, Elaine Hill, Elizabeth Zampino, Emily Carlson Marti, Emily R. Pfaff, Evan French, Farrukh M. Koraishy, Federico Mariona, Fred Prior, George Sokos, Greg Martin, Harold Lehmann, Heidi Spratt, Hemalkumar Mehta, Hongfang Liu, Hythem Sidky, J. W. Awori Hayanga, Jami Pincavitch, Jaylyn Clark, Jeremy Richard Harper, Jessica Islam, Jin Ge, Joel Gagnier, Joel H. Saltz, Joel Saltz, Johanna Loomba, John Buse, Jomol Mathew, Joni L. Rutter, Julie A. McMurry, Justin Guinney, Justin Starren, Karen Crowley, Katie Rebecca Bradwell, Kellie M. Walters, Ken Wilkins, Kenneth R. Gersing, Kenrick Dwain Cato, Kimberly Murray, Kristin Kostka, Lavance Northington, Lee Allan Pyles, Leonie Misquitta, Lesley Cottrell, Lili Portilla, Mariam Deacy, Mark M. Bissell, Marshall Clark, Mary Emmett, Mary Morrison Saltz, Matvey B. Palchuk, Melissa A. Haendel, Meredith Adams, Meredith Temple‐O'Connor, Michael G. Kurilla, Michele Morris, Nabeel Qureshi, Nasia Safdar, Nicole Garbarini, Noha Sharafeldin, Ofer Sadan, Patricia A. Francis, Penny Wung Burgoon, Peter Robinson, Philip R. O. Payne, Rafael Fuentes, Randeep Jawa, Rebecca Erwin‐Cohen, Rena Patel, Richard A. Moffitt, Richard L. Zhu, Rishi Kamaleswaran, Robert Hurley, Robert T. Miller, Saiju Pyarajan, Sam G. Michael, Samuel Bozzette, Sandeep Mallipattu, Satyanarayana Vedula, Scott Chapman, Shawn T. O'Neil, Soko Setoguchi, Stephanie S. Hong, Steve Johnson, Tellen D. Bennett, Tiffany Callahan, Umit Topaloglu, Usman Sheikh, Valery Gordon, Vignesh Subbian, Warren A. Kibbe, Wenndy Hernandez, Will Beasley, Will Cooper, William Hillegass, Xiaohan Tanner Zhang   +148 more
wiley   +1 more source

KCNQ1 rs163184 Variant Modulates Susceptibility to Classic and DPP-4 Inhibitor-Associated Bullous Pemphigoid. [PDF]

Int J Dermatol
Agiannitopoulos K, Achilla C, Poupounaki E, Meltzanidou P, Patsatsi A, Lazaridou E, Tzatzagou G, Lambropoulos A, Chatzikyriakidou A.   +8 more
europepmc   +1 more source

Longitudinal Taxonomic and Predicted Functional Gut Microbiome Responses to Tirzepatide and Semaglutide: An Exploratory Secondary Analysis of the OMDOT‐1 Randomized Controlled Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Glucagon‐like peptide‐1‐based therapies improve metabolic outcomes, but longitudinal gut microbiome dynamics remain poorly characterized. We compared taxonomic and predicted functional microbiome responses to tirzepatide and semaglutide in Type 2 diabetes.
Tomoaki Morioka, Daichi Miyaoka, Susumu Nakatani, Yoshinori Kakutani, Shoko Miyamoto, Yu Nagakura, Miho Uematsu, Takehiro Hirano, Hidekatsu Yae, Mako Yamamoto, Noriaki Sato, Kosuke Fujimoto, Masanori Emoto, Seiya Imoto, Satoshi Uematsu   +14 more
wiley   +1 more source

Comparison of DPP-4 Inhibitors

The Journal of Korean Diabetes, 2013
Nam Hoon Kim, Sin Gon Kim
openaire   +1 more source

Linagliptin, a Selective DPP-4 Inhibitor, Attenuates Ketamine- and Diazepam-Induced Deficits in Passive Avoidance Performance in Mice. [PDF]

Brain Sci
Fronc K, Listos P, Kasprzak P, Berger M, Słowik T, Kotlińska J, Poleszak E, Baranowska-Bosiacka I, Emilia L, Łupina M, Pysiewicz A, Listos J.   +11 more
europepmc   +1 more source

Association of GLP‐1 Receptor Agonists With Gastrointestinal and Liver Outcomes in Adults With Type 2 Diabetes: A Target Trial Emulation Study

Diabetes, Obesity and Metabolism, EarlyView.
Dazheng Zhang, Ying Lu, Xinyao Jian, Haoyuan Wang, Jacquelyn Hatch‐Stein, Ronen Stein, Jennifer Panganiban, Yong Chen   +7 more
wiley   +1 more source